Inquiry Basket
Loading ......
The Multiple Epitopes Antigen Designer (MEAD™) Platform is able to efficiently generate high-affinity antibodies, especially for identifying difficult-to-express proteins such as G protein-coupled receptors (GPCRs), ion channels, and other transmembrane proteins. Creative Diagnostics offers a professional Multiple Epitopes Antigen Designer (MEAD™) platform to meet the needs of polyclonal and monoclonal antibody development. With our expertise, we provide efficient, batch-to-batch consistency and scalable production methods to meet a variety of scientific research needs.
ProteinMaker™
High-speed Refrigerated Centrifuge
Ion Exchange Equipment
As an industry-trusted antibody manufacturer, Creative Diagnostics provides customized solutions with decades of professional experience in the development of antibodies, viral antigens, innovative diagnostic components and key detection reagents. We provide:
Creative Diagnostics provides comprehensive antibody discovery services using the MEAD platform to meet the diverse needs of researchers and developers in this field. Its advanced technologies and methods ensure the efficiency and accuracy of antibody production. We provide:
Antigen epitope prediction: We utilize bioinformatics tools to predict multiple epitopes of the same antigen, and construct peptide and protein fragment antigens for optimized screening to design antigens with high immunogenicity.
Antigen expression: Express the antigen fragments optimized by bioinformatics screening to construct a multi-epitope antigen library.
Polyclonal Antibody Production: Animals are immunized with a library containing multiple high-affinity antigen epitopes to obtain high-affinity polyclonal antibodies.
Monoclonal Antibody Production: We use a single antigen with high affinity screened from an antigen epitope library to immunize animals and obtain monoclonal antibodies through hybridoma technology.
Specific Protein Antibody Production: The MEAD™ platform can identify difficult-to-express proteins such as GPCRs, ion channels, and other transmembrane proteins, and efficiently generate high-affinity antibodies.
Antibody Screening: We use phage display technology, yeast display technology, antibody library screening, etc. to secondary screen antibodies with high affinity and specificity from a large number of antibody sequences.
Optimization Strategy: Improve the binding ability, stability and function of antibodies through point mutation, affinity maturation, structural modification and other methods.
Antibody Production: Large-scale production of antibodies through antibody humanization, antibody engineering, recombinant expression systems, etc.
Antibody Purification: We use protein A/G/L affinity purification, ion exchange chromatography, gel filtration chromatography and proprietary purification methods to remove impurities and improve antibody purity.
Antibody Characterization: Evaluate the concentration, purity, integrity, specificity and function of antibodies through ELISA, HPLC, biochip technology, etc.
Antibody Validation: All our antibodies will be verified by western blot, flow cytometry, cell function experiments, etc. to verify the biological activity and function of the antibodies.
Basic information communication: target antigen information, antibody application range, immune animal selection, etc.
Construction and screening of antibody libraries with different epitopes
Performance testing and parameter fine-tuning in customer analysis
Expanded production of determined antibodies according to customer needs
Provide quality control certificates, stability reports and comprehensive technical support
Creative Diagnostics uses the antigen epitope prediction program ISPIPab to accurately and reliably predict and evaluate antigens with multiple epitopes.
Creative Diagnostics uses an epitope prediction program to predict different epitopes of the same antigen and determines the affinity constants of different epitopes by ELISA.
The MEAD™ Platform leverages computational biology-driven multi-epitope integration to overcome limitations of single-epitope approaches, such as low target coverage and prolonged development cycles. Key advantages include:
Efficiency: Rapid screening of immunogenic epitopes using algorithms like NetMHCpan and BepiPred 3.0, reducing development time by 30%-50% compared to conventional methods.
Precision: Specialized in handling hard-to-express targets (e.g., GPCRs, ion channels, transmembrane proteins) by optimizing antigen conformation via molecular dynamics simulations.
Broad-Spectrum Recognition: Multi-epitope design enhances antibody specificity for complex targets, minimizing immune escape risks caused by epitope mutations.
Scalability: High-throughput automated workflows enable parallel processing of hundreds of targets, ideal for large-scale antibody library generation or vaccine development.
MEAD™ employs a "computational prediction + experimental validation" dual-loop optimization strategy:
Computational Screening: Epitopes are prioritized using antigenicity scores (IEDB tools), toxicity models (ToxinPred), and molecular docking (RosettaDock).
Experimental Rigor:
Small-Scale Validation: Surface Plasmon Resonance (SPR) and ELISA validate binding kinetics (KD values) during pilot production.
Batch Quality Control: HPLC purity checks and Western Blot specificity tests ensure<5% inter-batch variability.
Documentation: QC certificates and stability reports (accelerated degradation data) are provided to support downstream applications (e.g., IHC, flow cytometry).
Yes, MEAD™ offers end-to-end customization:
Target Analysis: AlphaFold 2-predicted 3D models guide epitope selection from extracellular loops of transmembrane proteins, avoiding hydrophobic regions.
Peptide Optimization: Post-translational modifications (phosphorylation, glycosylation) are simulated to enhance functional antibody recognition.
Immunization Strategies: Tailored protocols (e.g., full-length protein + peptide boosts) or humanized mouse models improve antibody compatibility.
Flexible Deliverables: Clients may request antigen design reports only or full-service antibody development (from epitope screening to purified products).
For high affinity antibody development using our Multiple Epitopes Antigen Designer (MEAD™) Platform, please contact your expert antibody manufacturer, Creative Diagnostics. From research-grade tools to industrial-scale antibody production, our team is ready to support your R&D innovation.
Loading ......
